Comparative analysis of humoral immune response upon the three first vaccines applied in Argentina: IgG production and neutralizing capacity against SARS-CoV-2.

GIAI C; SALASSA BN; ZARELLI VEP; BELLO O; VANRELL MC; OJEDA DS; GAMARNIK A; COLOMBO MI

HELIYON

Elsevier BV

Lugar: Amsterdam; Año: 2023

2405-8440

The population that has not received a SARS-CoV-2 vaccine is at high risk for infection whereas vaccination prevents COVID-19 severe disease, hospitalization, and death. In Argentina, to date, more than 50 million doses of vaccines against SARS-CoV-2 have been administered. The three main vaccines applied are Sputnik V, Oxford?AstraZeneca, and Sinopharm. In this study, we have compared the antibody response of voluntary individuals at day 0 (first dose vaccination day) and at 21-25 days post first and second dose. Our results indicate that at 21-25 days after the administration of the first doses of Sputnik V the large majority of the people vaccinated 80% (n=15) presented high humoral responses as determined by the measurement of IgG against the Spike protein and the Receptor Binding Domain (RBD). In the case of those vaccinated with AstraZeneca, the percentage was 80% (n=15) whereas this value was reduced to only 25% (n=16) in persons that received Sinopharm. However, after the second doses, most of the recipients had significant levels of antibodiesThe virus neutralizing capacity of the antibodies generated was evaluated using a pseudotyped VSV-SARS-CoV2 spike expressing eGFP and the data was analyzed by fluorescence microscopy and flow cytometry. The results indicate that a good correlation exists between the levels of IgG and the neutralizing capacity of the antibodies against the recombinant virus.Our results remark the importance of applying timely the second dose of Sinopharm. Thus, the present report provides data that will contribute to decisions making about the vaccine implementation plans of action for, not only our region but our country to support the fight against the COVID-19 global pandemic.